Versant Venture Capital VI, L.P.

This profile gathers the share dealings of Versant Venture Capital VI, L.P. across 12 companies, led by Black Diamond Therapeutics, Inc., Akero Therapeutics, Inc. and Oyster Point Pharma, Inc. In total, 269 filings cover trades dated from 24 June 2019 to 30 September 2025.

On the open market, the record shows 10 purchases worth €35.6M and 126 sales worth €92.1M. The net balance comes to €56.5M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2025, the count stands at no purchases and 10 sales.

Half of the purchases are above €3.1M and half below. 10 out of 10 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster. Ninety days after publication, 6 purchases show a median change of -0.6%, with the price up in 33% of them. These figures describe past trades and do not predict future prices.

The latest filing, published on 2 October 2025, reports an open-market sale of €1.9M in LENZ Therapeutics, Inc. The latest purchase dates back some time: it was published 2,192 days ago, on 20 October 2020. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.